Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemotherapy for nasopharyngeal cancer
NCT03581786Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Oct 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03581786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581786.